MD–MS program

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Retrieved on: 
Wednesday, September 20, 2023
Deformity, Surgeon, American Orthopaedic Foot and Ankle Society, Social, Annual, NUALS Arts and Literary Annual Meet, MD–MS program, Instrument, Trial of the century, Recurrence, Patient, Manuscript, Hammer toe, MD, Bunion, Poster, HVA, Micro, Dissection, Pharmaceutical industry, Nursing, Medical device, Medical imaging

The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.

Key Points: 
  • The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.
  • Additionally, at 36 months post-procedure, less than 5% of patients were unsatisfied with the overall results of the procedure (n=96).
  • The poster, which includes additional details, can be accessed by AOFAS meeting attendees on a kiosk at the Annual Meeting or on the mobile app.
  • The Company plans to submit its primary endpoint ALIGN3D™ manuscript for publication in a top-tier peer-reviewed foot and ankle journal later in 2023.

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Retrieved on: 
Friday, May 12, 2023
Health, General Health, Cognition, NCE, Rat, Cognitive deficit, Myelin, Therapy, Grey, Clinical trial, MD–MS program, Research, Biomarker, Multiple sclerosis, Remyelination, VEP, Trial of the century, MS, Regenerative medicine, Development, MRI, State Administrative Expenses, Magnetic resonance imaging, HIV disease progression rates, Patient, Administration, Frequency, Mouse, White matter, Visual acuity, Axon, Disease, Pharmaceutical industry, Medical imaging, Vaccine

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023.
  • Cash Position: As of March 31, 2023, Frequency had cash, cash equivalents and marketable securities of $66.7 million (excluding restricted cash), or $55.0 million net of debt.
  • Excluding stock-based compensation expense of $0.8 million, research and development expenses for the three months ended March 31, 2023 were $10.6 million.
  • Excluding stock-based compensation expense of $2.6 million, general and administrative expenses for the three months ended March 31, 2023 were $6.6 million.

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 10, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, SNHL, Therapy, Trial of the century, Axon, MRI, Biomarker, Frequency, State Administrative Expenses, Sensorineural hearing loss, MD–MS program, MS, Multiple sclerosis, Patient, Regenerative medicine, Speech perception, Clinical trial, Administration, VEP, Myelin, Development, Magnetic resonance imaging, Remyelination, Pharmaceutical industry, Medical imaging, Cryptocurrency

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
  • MS in characterized by demyelination, stripping axons of the myelin sheaths that support neuronal signal conduction and axonal survival.
  • Net Loss: Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable period of 2021.
  • Net loss was $81.6 million for the full year ended December 31, 2022, as compared to $84.7 million for the comparable period of 2021.

University of Maryland's Smith School and the Deloitte Foundation to Fund Scholarships for Students Pursuing a Fifth-year Master's Program in Accounting

Retrieved on: 
Wednesday, January 25, 2023
University, Accounting, Workplace, Smith School, Book, Student, Robert H. Smith School of Business, Education, Workforce, Environment, Equitable, MADE, CPA, MD–MS program, UMD, Interest, University of Maryland School of Public Policy, School, Business, MS, Nursing

The Deloitte Foundation expects to fund $30 million in scholarships for students over the next several years, including students interested in pursuing a fifth-year master's degree in accounting, master's of tax or master's of accounting with a concentration in audit, advisory or tax through the Deloitte Foundation Accounting Scholars Program.

Key Points: 
  • The Deloitte Foundation expects to fund $30 million in scholarships for students over the next several years, including students interested in pursuing a fifth-year master's degree in accounting, master's of tax or master's of accounting with a concentration in audit, advisory or tax through the Deloitte Foundation Accounting Scholars Program.
  • DFASP participating schools and the Deloitte Foundation will cover 100% of tuition (excluding books and living expenses) for selected students.
  • "We are very excited to bring the Deloitte Foundation Accounting Scholars Program to more colleges and universities this year to engage more diverse students in pursuing a career in accounting or tax."
  • Interested students should apply for admission to the Smith School, and then separately apply to be considered for the DFASP.

D2 Consulting and the Dayton Center for Neurological Disorders ("DCND"), announce the successful launch of a digital remote monitoring system for patients with MS

Retrieved on: 
Tuesday, August 31, 2021
Industry, Company, Lists of diseases, FACN, MS, Patient, Quality of life, D.O, Today, Complexity Science Hub Vienna, Digital technology, Central nervous system, Time, MD–MS program, Business development, Inflammation, Health, Neurology, Huntsville Hospital System, Medical director, Pharmacy Council of India, Scar, HIV disease progression rates, HUB, Hematology, Brain, Technology, Multiple sclerosis, Pharmaceutical industry, Medical device

ST. LOUIS, Aug. 31, 2021 /PRNewswire-PRWeb/ -- D2 Consulting and the Dayton Center for Neurological Disorders ("DCND"), Centerville OH, announces the successful launch of a digital remote monitoring system for patients diagnosed with multiple sclerosis (MS).

Key Points: 
  • ST. LOUIS, Aug. 31, 2021 /PRNewswire-PRWeb/ -- D2 Consulting and the Dayton Center for Neurological Disorders ("DCND"), Centerville OH, announces the successful launch of a digital remote monitoring system for patients diagnosed with multiple sclerosis (MS).
  • MS is a chronic and often debilitating illness impacting nearly 1 million patients in the U.S. over the age of 181.
  • Established in 2008, D2 Consulting (D2) is recognized as the industry's leading provider of commercialization services to the life sciences industry.
  • D2 assists emerging and established pharmaceutical, biopharmaceutical and medical device manufacturers to develop and execute strategic business initiatives, ensuring successful launch, distribution, and reimbursement.

National Kidney Foundation Publishes 23 Recommendations to Move Thousands of Patients from Dialysis to Transplant

Retrieved on: 
Tuesday, July 27, 2021
Medical specialties, Medicine, Clinical medicine, National Kidney Foundation, Kidney diseases, Kidney transplantation, Kidney disease, Organ transplantation, Kidney failure, National Kidney Foundation Singapore

Today, while nearly 100,000 people are on the waitlist for a kidney transplant , only 22,817 Americans received a kidney transplant in 2020.

Key Points: 
  • Today, while nearly 100,000 people are on the waitlist for a kidney transplant , only 22,817 Americans received a kidney transplant in 2020.
  • Research recommendations developed by the panel center on seven key priorities:
    Improve management and readiness of the kidney waitlist.
  • Hispanic or Latino people are 1.3 times more likely than non-Hispanic or non-Latino people to have kidney failure.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org .

P.volve Launches a First to Market Clinically Backed Program Revolutionizing Women's Wellness Through Nutrition and Exercise Tied to Menstrual Phases

Retrieved on: 
Monday, July 26, 2021
Quality of life, Wellness

NEW YORK, July 26, 2021 /PRNewswire/ --Omni-channel dynamic fitness method, P.volve , today announces its newest women's health and wellness program - Phase & Function.

Key Points: 
  • NEW YORK, July 26, 2021 /PRNewswire/ --Omni-channel dynamic fitness method, P.volve , today announces its newest women's health and wellness program - Phase & Function.
  • Phase & Function launches as a clinically backed, first-to-market program, with dedicated cycle tracking, a personalized workout, and nutrition plan, as well as expert-led education.
  • The team of experts have also conducted live Q&A sessions as an added information resource online (via desktop and mobile web).
  • She is certified in Adult Weight Management Levels I & II and is well versed in both the clinical and private space.

P.volve Launches a First to Market Clinically Backed Program Revolutionizing Women's Wellness Through Nutrition and Exercise Tied to Menstrual Phases

Retrieved on: 
Monday, July 26, 2021

NEW YORK, July 26, 2021 /PRNewswire/ -- Omni-channel dynamic fitness method, P.volve, today announces its newest women's health and wellness program - Phase & Function.  Combining movement, mind, and meals, Phase & Function is powered by periods, with information and ideas to help women harness the four phases of the menstrual cycle to look and feel amazing. It is uniquely designed to help women get their bodies to work as they naturally should and revolutionizes the management of traditional menstrual symptoms like PMS and PMDD through dedicated and personalized nutrition and exercise plans created to sync with the four phases of the menstrual cycle.

Key Points: 
  • Phase & Function launches as a clinically backed, first-to-market program, with dedicated cycle tracking, a personalized workout, and nutrition plan, as well as expert-led education.
  • The team of experts have also conducted live Q&A sessions as an added information resource online (via desktop and mobile web).
  • This first-to-market approach is the next phase of cycle syncing to work with your body and feel empowered all month long.
  • She is certified in Adult Weight Management Levels I & II and is well versed in both the clinical and private space.